Weight Loss Drugs Global Market Analysis, Trends, Growth, Research And Forecast 2033

The weight loss drugs market size has grown exponentially in recent years. It will grow from $1.94 billion in 2023 to $2.87 billion in 2024 at a compound annual growth rate (CAGR) of 47.8%. The growth in the historic period can be attributed to increasing obesity rates, lifestyle changes, awareness and education, early diagnosis of medical conditions, rising healthcare expenditure.

The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $12.17 billion in 2028 at a compound annual growth rate (CAGR) of 43.5%. The growth in the forecast period can be attributed to increasing geriatric population, social media influence, fitness and wellness trends, cultural perception of beauty, pharmaceutical industry investments. Major trends in the forecast period include technological advancements, focus on non-prescription solutions, personalized medicine, combination therapies, product innovation, post-market surveillance.

Market Overview -
Weight loss drugs are pharmaceutical substances that help reduce appetite and food cravings, leading to a decrease in calorie intake and weight loss. These drugs are FDA-approved and are prescribed by doctors to treat obesity or overweight individuals who have other weight-related medical conditions such as high blood pressure, type 2 diabetes, or high cholesterol.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13761&type=smp

Rising Obesity Rates Fueling Surge in the Weight Loss Drugs Market
Increasing obesity rates is expected to propel the growth of the weight loss drugs market going forward. Obesity rate refers to the proportion of individuals in a population who have a body mass index (BMI) equal to or greater than 30. Weight loss drugs are medications used in obesity to help individuals achieve weight loss by either reducing appetite, increasing feelings of fullness, or interfering with the absorption of nutrients For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government organization, adult obesity rates exceeded 35% in 19 states in 2021 and 22 states in 2022. Further, adult obesity prevalence was at or above 35% in 2022. Further, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, it is estimated that over 4 billion people are expected to be obese by 2035. Therefore, the rise in the increasing obesity rates is driving the growth of the weight loss drugs market.

Competitive Landscape -
Major companies operating in the weight loss drugs market report are Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG, Bristol Myers Squibb, Sanofi S.A., AstraZeneca plc, LG Chem, GlaxoSmithKline, Takeda Pharmaceutical Company, Eli Lilly and Company, Bayer AG, Amgen Inc., Boehringer Ingelheim group, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Hisun Pharmaceutical, Taj Pharmaceuticals Ltd, Zhongshan Pharmaceutical Co. Ltd., Dm Pharma, Lunan Pharmaceutical Group Corporation, Wolfson Berg Ltd., Swiss Research Labs Ltd.

Innovative Developments In Weight Loss Drugs Market With Zepbound Approval
Major companies operating in the weight loss drug market are developing innovative products such as Zepbound (tirzepatide) injection to better serve patients. Zepbound is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least 1 weight-related condition. Zepbound has the potential to be a commercially successful drug, as it is the first and only FDA-approved obesity treatment that activates both GIP and GLP-1 receptors.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report

Key Segments -

The weight loss drugs market covered in this report is segmented -

1) By Type: Liquid, Tablets, Capsules
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Weight-Reducing Aid, Fat Absorption Inhibitors, Metabolic Boosters

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.